Skip to main content

Vonoprazan 20 mg

any
Product Description
  • A potassium-competitive acid blocker (PCAB), the first and only FDA-approved PCAB for erosive and non-erosive gastroesophageal reflux disease and eradication of H.pylori in combination with antibiotic.
  • Has greater inhibition of gastric acid secretion than PPIs.
  • Preferable over PPIs treatment in Acid-Related Disease due to its rapid onset of action, longer duration of action.
  • Has enhanced eradication rate in H.pylori treatment compared to PPIs.
  • Suppress acid for 2-3 hours, over 24 hours.
  • Unlike Most PPIs, can be taken with or without food (reduces dependance on meal timing)